- Home
- MCRB vs GLSI Comparison
MCRB vs GLSI Comparison
Compare MCRB & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- GLSI
- Stock Information
- Founded
- MCRB 2010
- GLSI 2006
- Country
- MCRB United States
- GLSI United States
- Employees
- MCRB N/A
- GLSI N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- GLSI Health Care
- Exchange
- MCRB Nasdaq
- GLSI Nasdaq
- Market Cap
- MCRB 125.7M
- GLSI 134.6M
- IPO Year
- MCRB 2015
- GLSI 2020
- Fundamental
- Price
- MCRB $19.44
- GLSI $12.18
- Analyst Decision
- MCRB Hold
- GLSI Strong Buy
- Analyst Count
- MCRB 4
- GLSI 1
- Target Price
- MCRB $73.67
- GLSI $39.00
- AVG Volume (30 Days)
- MCRB 126.4K
- GLSI 45.1K
- Earning Date
- MCRB 08-06-2025
- GLSI 08-14-2025
- Dividend Yield
- MCRB N/A
- GLSI N/A
- EPS Growth
- MCRB N/A
- GLSI N/A
- EPS
- MCRB 10.22
- GLSI N/A
- Revenue
- MCRB N/A
- GLSI N/A
- Revenue This Year
- MCRB N/A
- GLSI N/A
- Revenue Next Year
- MCRB N/A
- GLSI N/A
- P/E Ratio
- MCRB $1.98
- GLSI N/A
- Revenue Growth
- MCRB N/A
- GLSI N/A
- 52 Week Low
- MCRB $6.53
- GLSI $8.06
- 52 Week High
- MCRB $26.40
- GLSI $16.50
- Technical
- Relative Strength Index (RSI)
- MCRB 69.44
- GLSI 56.92
- Support Level
- MCRB $15.79
- GLSI $11.41
- Resistance Level
- MCRB $18.12
- GLSI $12.35
- Average True Range (ATR)
- MCRB 1.51
- GLSI 0.67
- MACD
- MCRB 0.28
- GLSI -0.06
- Stochastic Oscillator
- MCRB 97.69
- GLSI 52.20
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.